# A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects

> **NCT05955027** · PHASE1 · COMPLETED · sponsor: **Nanjing Zenshine Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** ZX-7101A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05955027
- **Lead sponsor:** Nanjing Zenshine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-08
- **Primary completion:** 2023-08-05
- **Final completion:** 2023-12-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955027, "A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05955027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*